Executive Leadership

Chirag Patel has served as Co-Chief Executive Officer, President and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously was Co-Founder of Amneal and served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2005 until the combination with Impax Laboratories in 2018. With his brother, Chintu Patel, Mr. Patel has also invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv Biosciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Earlier in his career, Mr. Patel co-founded technology companies NextGen Technologies and Veriprise Wireless. In 2022, Mr. Patel served as the Chair of the Association for Accessible Medicines (AAM) Board of Directors. He continues to serve as an inaugural member of the CEO Advisory Committee for the International Generic and Biosimilar Medicines Association (IGBA). Mr. Patel also serves as a Managing Trustee for the Liberty Science Center of New Jersey and a Trustee for the Foundation for Morristown Medical Center. He is a recipient of the Ernst & Young National Entrepreneur of the Year® 2011 Life Sciences Award. Mr. Patel supports various philanthropic causes and, together with his wife, Priti Patel, established the Niswarth International Foundation in 2013. The Foundation aims to bring fresh water, sanitation, nutrition and education to underprivileged children. Mr. Patel received his bachelor’s degrees in Commerce from H.A. College of Commerce, India, and in Business Administration from New Jersey City University. He also holds an honorary Doctorate of Humane Letters from New Jersey City University in recognition of his efforts to serve others.

Chintu Patel has served as Co-Chief Executive Officer and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2002 until the combination with Impax Laboratories in 2018. With his brother, Chirag Patel, Mr. Patel also co-founded and invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv BioSciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Before founding Amneal, Mr. Patel was a pharmacist and senior-level manager with Eckerd Pharmacy from 1994 to 2002, where he won numerous awards. Mr. Patel has been a featured speaker at the Hauppauge Industrial Association in New York and serves on the boards of the Long Island Association, Long Island University, and is a recipient of the Ernst & Young National Entrepreneur of the Year® 2011 Life Sciences Award. Mr. Patel and his wife, Falguni Patel, run the Irada International Foundation, which focuses on health, education, and community outreach projects in India and the United States. Mr. Patel holds a bachelor’s degree in Pharmacy from Rutgers College of Pharmacy. He also holds an honorary Doctor of Science degree from Long Island University Pharmacy in recognition of his contributions toward quality, integrity and innovation in pharmaceuticals.

Tasos is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Information Technology. He brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics/data industries. Tasos most recently served as Alcresta Therapeutics, Inc.’s Chief Financial Officer from 2016 to 2020, where he led the company’s finance, corporate development, information technology and human resources functions, and was instrumental in supporting the commercialization of a novel therapy to help critically ill patients and expand the company’s R&D pipeline. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., from 2011 to 2015. In that role, he led finance and corporate development functions in delivering robust global organic growth as well as growth through licensing and acquisitions. Before joining Ikaria, Tasos served as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation for seven years, and previously held financial and general management roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb. He currently serves as a Director on the boards of Kadmon Holdings and Zep Inc. He holds a B.S. in Mathematics and Finance from Gwynedd Mercy University and an M.B.A. from Drexel University.

Nikita leads Amneal’s Human Resources, Internal Communications and Corporate Social Responsibility functions. She also partners with the Co-CEOs to lead the creation and execution of the company’s long-term Corporate Strategy. Nikita joined Amneal in January 2014 as Senior Vice President, Human Resources & Corporate Affairs, and has served roles of increasing responsibility as a member of the company’s executive leadership team. Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, then a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held leadership roles at AT&T and Deloitte. She holds a master’s degree in accounting and auditing from Gujarat University, India and is a certified public accountant.

Jason Daly has served as our Executive Vice President, Chief Legal Officer and Corporate Secretary since March 2025. Prior to that time, Mr. Daly served as our Senior Vice President, Chief Legal Officer and Corporate Secretary since January 2022. Mr. Daly is responsible for leading Amneal’s global legal and corporate compliance strategies with a focus on creating value for Amneal as it pursues its mission of delivering high-quality, affordable medicines to the U.S. and select international markets. He brings substantial experience leading the legal and commercial strategies for global pharmaceutical and medical device companies, including Teva Pharmaceuticals, Inc., where he held various roles, including Senior Vice President, U.S. Market Access and General Counsel – U.S. Generics & North American Commercial. Prior to Teva, Mr. Daly served nearly a decade in various legal and international commercial leadership roles with The Straumann Group, a Swiss medical device company. He has worked in private practice and was a law clerk to the Hon. Mary Lisi in the United States District Court in Rhode Island. Mr. Daly holds degrees from the University of Pennsylvania Law School and the University of Rhode Island, and is licensed to practice law in New Jersey, Massachusetts, and Rhode Island. He also holds professional certificates from The Kellogg School of Management, The Wharton School of Business, and The Boston University School of Management.

Greg is responsible for identifying, evaluating and executing transactions that align with the strategic vision of the company, including partnerships, in- and out-licensing agreements and mergers & acquisitions (M&A). He joined Amneal from Tarsadia Investments, where he most recently served as Portfolio Manager, Healthcare/Crossover Strategy, managing the firm’s public equities focused on small-and mid-cap companies in life sciences. Greg has also previously served as a Vice President at Tarsadia with responsibilities for M&A, where he led several acquisitions for the firm’s portfolio of companies. Greg began his career on Wall Street at Lazard Frères & Co. as an analyst in M&A advisory. Greg holds a master’s degree in International Relations and Economics and a bachelor’s degree in Economics and International Studies, both from Johns Hopkins University

Andy is focused on accelerating the sales, marketing and distribution of our evolving generics portfolio. Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc. Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.

Joe has top-level leadership responsibility for all areas of our Specialty Commercial organization, including sales, marketing, market access and commercial operations. He has over 30 years of Pharma/BioTech and leadership experience. Prior to joining Amneal in April 2023, he served as Chief Commercial Officer, Senior Vice President at Halozyme, an American biotech company that develops novel oncology/HIV therapies and commercial testosterone products. In this role, Joe led the sales, marketing, operations/analytics, market access and all commercial functions. Prior to Halozyme, Joe served as VP, U.S. Sales Autoimmune & Rare Disease, Mallinckrodt Pharmaceuticals. He also served in numerous senior leadership roles at Novo Nordisk, Inc. including VP, U.S. Sales Biopharmaceutical Division, Marketing Brand Director for Women’s Health Products, and Head of their Sales Operations & Analytics Dept (which included Market Research, Forecasting, IC). Additionally, he held several other roles including Market Access Account Manager, Operations Lead, Director of L&D, Manager of Strategic Alliances and various leadership roles at Pfizer and Pharmacia Corporation. Joe started his career as a Primary Care Sales Specialist at The Upjohn Company. Joe holds a Bachelor of Science degree from The Pennsylvania State University in Accounting with an emphasis in Physiology and leadership certifications from the Wharton School of The University of Pennsylvania and Institute of Professional Excellence in Coaching.

Dr. Kone has leadership responsibility for Amneal’s Generic Research & Development activities, including overseeing the company’s global Complex Pharmaceutical Dosage Development, Regulatory Affairs and Portfolio and Project Management activities. He brings substantial R&D experience to Amneal and has served roles of increasing responsibility since joining the company in 2005. During his tenure, Dr. Kone has contributed significantly to the expansion of Amneal’s technical capabilities across new dosage forms, including leading the development of advanced programs in complex generic liquids, nasal sprays, topicals, transdermals, ophthalmics and inhalation. He has also played a key role in implementing innovative regulatory strategies that resulted in the delivery of several first-to-file and first-to-market opportunities and is deeply experienced in product lifecycle management. Prior to joining Amneal, Dr. Kone held R&D leadership roles for Zydus and Sun Pharmaceuticals. Dr. Kone received his Ph.D in Pharmacy from Andhra University, holds several patents and his research has been published in several journals of international acclaim.

Dr. Desai leads the expansion of Amneal’s Specialty pipeline, including overseeing clinical development activities and Medical Affairs operations supporting in-development and launched products. He brings more than 25-years of experience in pharma/biotech clinical development (Phase I to IV) as well as deep expertise in U.S. and Global Medical Affairs and life cycle management. Dr. Desai joins Amneal from Actinium Pharmaceuticals, Inc. where he served as Chief Medical Officer. Prior to that, he was Vice President, U.S. Medical Affairs, Oncology for GlaxoSmithKline, and successfully led the creation of launch readiness plans for four indications of three novel oncology products. Dr. Desai’s career also includes several years at Janssen where he helped lead the creation and execution of the company’s oncology pipeline. He also previously held senior medical affairs and clinical research leadership roles for Eli Lilly & Company; Takeda, Inc.; Eisai, Inc. Dr. Desai holds a Doctor of Medicine degree as well as a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from B.J. Medical College and Civil Hospital in Ahmedabad, India. His work is widely published in several prominent medical and scientific journals around the world.

Sanjay has oversight for all aspects of Amneal’s global Quality operations. He has extensive experience managing Quality, Operations, and Validation as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Previously, Sanjay served as President, India Operations, with oversight for Amneal India operations, including managing the overall productivity and quality deliverables. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. Sanjay is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences. He holds a degree in Pharmacy, a post graduate degree in Quality Management (Masters in Science, Quality Management), and Ph.D. in Operation Management.

Pranav leads Amneal’s global direct and indirect procurement strategies, with a focus on leveraging the company’s growing scale to drive cost-savings, boost efficiencies and enhance the value of goods/services we receive from vendors and partners. Pranav joined Amneal in 2005 to help build what was then a fledgling company. He quickly advanced his career into various leadership capacities, including previous roles as Global Director of Purchasing and most recently Vice President, Strategic Sourcing & Supply Management. His expertise in procurement has been instrumental to Amneal’s acquisitions of key assets in US and India as well as the launch of several first-to-market products. Pranav has nearly 20 years of experience and deep relationships across the global pharmaceutical industry. He holds an MBA from the University of Houston.

Sandeep leads all aspects of our India and Ireland-based operations, including manufacturing, projects & engineering, EHS and administrative services. Sandeep is a deeply experienced operations executive with more than 28 years of expertise, including a specialized focus on automation and digitization. He joins Amneal from Mumbai-based Cipla Ltd., where he most recently served as Executive Vice President, Head International Operations & CMG, responsible for 13 of the company’s manufacturing plants. Over his tenure with the company, Sandeep was instrumental in leading the automation, digitization and simplification project resulting in a touchless factory model that earned the Lighthouse Accreditation from the World Economic Forum in 2022. Prior to joining Cipla, Sandeep served as Senior Vice President, Biologics and Pharma OSD & Injectables for Wockhardt; as a Managing Director for Cipla Biotech; and as a Senior Production Executive for Intas Pharmaceuticals Ltd. He holds a Master of Business Administration and a Bachelor of Pharmacy from Pune University.

Maryll leads the company’s efforts to develop top-level regulatory strategies supporting the launch and commercialization of key products across the specialty, biosimilar, and generic portfolios. She also leads Amneal’s government relations and public policy interface with state and federal policymakers in the legislative and executive branches. Maryll joined Amneal from FDA’s Center for Drug Evaluation & Research (CDER), where she most recently served as Director of the Office of Generic Drug Policy, overseeing all regulatory and policy matters in the Office of Generic Drugs’ generic drug program. She previously served FDA in various senior leadership roles in CDER and the Office of the Commissioner, and as Associate Chief Counsel for Drugs in FDA’s Office of Chief Counsel. Prior to joining FDA, Maryll served as an associate with Zuckerman Spaeder LLP, specializing in food and drug and criminal defense matters. She began her legal career at Willkie Farr & Gallagher LLP, and clerked for the United States District Court for the District of Columbia. Maryll holds a J.D. from New York University School of Law, an M.A. in English Literature from the University of Texas at Austin, and a B.A. from the University of Michigan in Afro-American and African Studies and English.

Upendra leads our commercial operations in India and Emerging Markets in Southeast Asia, Middle East and Africa. He is a seasoned pharmaceutical leader with over 25+ years of experience with a proven track record in strategic business management, navigating complex regulatory environments and fostering team growth. Most recently, he served as the Commercial Head & EVP at GSK India. During his tenure at GSK, he worked in leadership roles in Indonesia, Sri Lanka, and the Middle East, and successfully managed market expansions, regulatory challenges, and high-value portfolios. He holds a Post Graduate Programme in Management from Indian Institute of Management (IIM), Indore and a Bachelor’s in Science (Chemistry) from Sheth L.U.J. College of Arts & Sir M.V. College of Science, Mumbai.